New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 7, 2014
14:48 EDTTC, SNSS, MUR, EWP, MDCOHigh option volume stocks: TC SNSS MUR EWP MDCO
News For TC;SNSS;MUR;EWP;MDCO From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 20, 2014
09:48 EDTMDCOBrdiger Management reports 5.1% passive stake in The Medicines Co.
October 14, 2014
07:08 EDTTCThompson Creek reports Q3 operating results
Subscribe for More Information
October 13, 2014
07:25 EDTMDCOEuropean Association of Cardiothoracic Surgery to hold annual meeting
28th EACTS Annual Meeting is being held in Milan, Italy on October 11-15.
October 10, 2014
07:14 EDTMDCOThe Medicines Co's Q3 Angiomax estimate lowered at Credit Suisse
Subscribe for More Information
05:47 EDTSNSSStocks with implied volatility movement; SNSS GPOR
Subscribe for More Information
October 9, 2014
16:57 EDTMDCOThe Medicines Co. announces journal publication of SOLO II phase 3 trial
The Medicines Company announced the publication of the results from the SOLO II phase 3 clinical trial of ORBACTIV, or oritavancin, for injection in the journal Clinical Infectious Diseases. ORBACTIV, is the first and only single dose intravenous antibiotic approved by FDA for the treatment of adults with Acute Bacterial Skin and Skin Structure Infections, or ABSSSI, caused or suspected to be caused by susceptible isolates of designated Gram-positive pathogens. The publication reported that a single, once only, 1200 mg intravenous dose of ORBACTIVTM was non-inferior to twice-daily intravenous dosing of vancomycin given for 7 to 10 days in patients with ABSSSI caused or suspected to be caused by Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus. A single 1200 mg IV dose of ORBACTIV results in efficacy in ABSSSIs that is comparable and statistically non-inferior to vancomycin administered intravenously for 7-10 days. ORBACTIV had a safety profile comparable to vancomycin when monitored for up to 60 days following a single dose, with similar intensity, onset and duration of AEs.
October 8, 2014
07:19 EDTSNSSCBI to hold a conference
Subscribe for More Information
05:45 EDTSNSSStocks with implied volatility movement; GTAT SNSS
Stocks with implied volatility movement; GT Advanced (GTAT) 403, Sunesis (SNSS) 164 according to iVolatility.
October 7, 2014
10:02 EDTSNSSOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
07:50 EDTSNSSSunesis downgraded to Sell from Buy at UBS
Subscribe for More Information
06:41 EDTSNSSSunesis downgraded to Hold from Buy at Cantor
Cantor Fitzgerald downgraded Sunesis to Hold after removing Qinprezo from its model following the Phase III VALOR trial failure. The firm thinks the stock will be capped to a multiple of cash in the near-term, or roughly $2 per share. Sunesis was also downgraded this morning at Roth Captial.
06:22 EDTSNSSSunesis downgraded to Neutral from Buy at Roth Capital
Subscribe for More Information
06:09 EDTSNSSStocks with implied volatility below IV index mean; ADHD SNSS
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use